ATE433448T1 - Kondensierte heterocyclen und deren verwendungen - Google Patents

Kondensierte heterocyclen und deren verwendungen

Info

Publication number
ATE433448T1
ATE433448T1 AT04717339T AT04717339T ATE433448T1 AT E433448 T1 ATE433448 T1 AT E433448T1 AT 04717339 T AT04717339 T AT 04717339T AT 04717339 T AT04717339 T AT 04717339T AT E433448 T1 ATE433448 T1 AT E433448T1
Authority
AT
Austria
Prior art keywords
condensed heterocycles
heterocycles
condensed
Prior art date
Application number
AT04717339T
Other languages
English (en)
Inventor
Brian Aquila
Michael Block
Audrey Davies
Jayachandran Ezhuthachan
Sandra Filla
Richard Luke
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0300627A external-priority patent/SE0300627D0/xx
Priority claimed from SE0301138A external-priority patent/SE0301138D0/xx
Priority claimed from SE0301697A external-priority patent/SE0301697D0/xx
Priority claimed from SE0302826A external-priority patent/SE0302826D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE433448T1 publication Critical patent/ATE433448T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04717339T 2003-03-07 2004-03-04 Kondensierte heterocyclen und deren verwendungen ATE433448T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0300627A SE0300627D0 (sv) 2003-03-07 2003-03-07 Novel fused heterocycles and uses therof
SE0301138A SE0301138D0 (sv) 2003-04-15 2003-04-15 Novel fused heterocycles and uses thereof
SE0301697A SE0301697D0 (sv) 2003-06-10 2003-06-10 Novel fused heterocycles and uses thereof
SE0302826A SE0302826D0 (sv) 2003-10-24 2003-10-24 Novel fused heterocycles and uses thereof
PCT/SE2004/000304 WO2004078758A1 (en) 2003-03-07 2004-03-04 Novel fused heterocycles and uses thereof

Publications (1)

Publication Number Publication Date
ATE433448T1 true ATE433448T1 (de) 2009-06-15

Family

ID=32966643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04717339T ATE433448T1 (de) 2003-03-07 2004-03-04 Kondensierte heterocyclen und deren verwendungen

Country Status (24)

Country Link
US (1) US20060270689A1 (de)
EP (1) EP1601673B1 (de)
JP (2) JP3947758B2 (de)
KR (1) KR20050107784A (de)
AR (1) AR043487A1 (de)
AT (1) ATE433448T1 (de)
AU (1) AU2004218080B2 (de)
BR (1) BRPI0408150A (de)
CA (1) CA2518224C (de)
CY (1) CY1109300T1 (de)
DE (1) DE602004021477D1 (de)
DK (1) DK1601673T3 (de)
ES (1) ES2326647T3 (de)
IS (1) IS8036A (de)
MX (1) MXPA05009577A (de)
MY (1) MY141583A (de)
NO (1) NO20054340L (de)
NZ (1) NZ542227A (de)
PL (1) PL1601673T3 (de)
PT (1) PT1601673E (de)
SI (1) SI1601673T1 (de)
TW (1) TW200510427A (de)
UA (1) UA81470C2 (de)
WO (1) WO2004078758A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003223786A1 (en) 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US7557115B2 (en) 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
EP1692112A4 (de) 2003-12-08 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
UY29070A1 (es) * 2004-08-18 2006-03-31 Astrazeneca Ab Enantiómeros de heterocíclicos fusionados y sus usos
JP4545196B2 (ja) * 2005-01-19 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
AU2008265600B2 (en) * 2007-06-21 2013-10-31 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
CN114478429B (zh) * 2020-11-13 2023-11-17 中国科学院大连化学物理研究所 一种3-烷硫基异噻唑衍生物及其合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CN1575177A (zh) * 2000-12-11 2005-02-02 图拉里克公司 Cxcr3拮抗剂
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
JP2005511581A (ja) * 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE447577T1 (de) * 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
DE60232994D1 (de) * 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) * 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
EP1463733B1 (de) * 2001-12-06 2007-09-05 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
US7244723B2 (en) * 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
CN100381437C (zh) * 2002-04-17 2008-04-16 赛特凯恩蒂克公司 化合物、组合物和方法
WO2003097053A1 (en) * 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003223786A1 (en) * 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004006865A2 (en) * 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
JP2007520435A (ja) * 2003-06-20 2007-07-26 カイロン コーポレイション 抗癌剤としてのピリジノ［１，２−ａ］ピリミジン−４−オン化合物
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
KR20070072598A (ko) * 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 인돌 및 벤지미다졸 유도체

Also Published As

Publication number Publication date
DK1601673T3 (da) 2009-08-24
EP1601673A1 (de) 2005-12-07
HK1084390A1 (en) 2006-07-28
PL1601673T3 (pl) 2009-10-30
CA2518224C (en) 2010-06-15
NZ542227A (en) 2008-12-24
SI1601673T1 (sl) 2009-10-31
TW200510427A (en) 2005-03-16
AU2004218080A1 (en) 2004-09-16
US20060270689A1 (en) 2006-11-30
MXPA05009577A (es) 2005-12-12
EP1601673B1 (de) 2009-06-10
AU2004218080B2 (en) 2008-01-03
MY141583A (en) 2010-05-14
JP2007063257A (ja) 2007-03-15
ES2326647T3 (es) 2009-10-16
JP2006519853A (ja) 2006-08-31
DE602004021477D1 (de) 2009-07-23
WO2004078758A1 (en) 2004-09-16
JP3947758B2 (ja) 2007-07-25
PT1601673E (pt) 2009-07-29
IS8036A (is) 2005-09-19
AR043487A1 (es) 2005-08-03
BRPI0408150A (pt) 2006-03-21
KR20050107784A (ko) 2005-11-15
NO20054340L (no) 2005-09-26
CA2518224A1 (en) 2004-09-16
CY1109300T1 (el) 2014-07-02
UA81470C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE433448T1 (de) Kondensierte heterocyclen und deren verwendungen
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
CY2016027I2 (el) Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων
DE60326611D1 (de) N und dergleichen
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE60237726D1 (de) Roll-/Gleitelement und Rollvorrichtung
DE60321401D1 (de) Demodulationseinrichtung und demodulationsverfahren
DE502004009028D1 (de) Scheinwerfer und Scheinwerferelement
DE10397003A5 (de) Biosensor, Biosensorchip und Biosensoreinrichtung
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE60316588D1 (de) Neue lactame und deren verwendungen
DE60331729D1 (de) Audiocodierungsverfahren und audiocodierungseinrichtung
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
DE60333629D1 (de) Neue phospholipasen und deren verwendungen
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE60303480D1 (de) Sensorenanordnung und Halteklammer dafür
DE60304229D1 (de) Pinselabflacher und mit Pinselabflacher ausgerüstete Zeichenvorrichtung
EP1583528A4 (de) Nf-kb inhibitoren und ihre verwendungen
ATE446301T1 (de) Ausgewählte kondensierte heterocyclen und deren anwendung
DE602004032139D1 (de) Festes schmiermittel und gleitglied
EP1812055A4 (de) Chlamydien-antigene und ihre verwendungen
EP1687398A4 (de) Hiv-abhängige expressionskonstrukte und verwendungen dafür
ITMI20021373A1 (it) Mescole polimeriche e loro uso
DE60317477D1 (de) Polypropylenzusammensetzung und daraus hergestellter film

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601673

Country of ref document: EP